Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
34.10
0.00 (0.00%)
At close: Sep 4, 2026, 4:00 PM EDT
34.44
+0.34 (1.00%)
Pre-market: Sep 8, 2026, 7:41 AM EDT
Amylyx Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
136
Market Cap
4.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 87.37M | -293.42M | -77.06% |
| Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
| Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
| Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
| Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
| Dec 31, 2019 | 1.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Amneal Pharmaceuticals | 3.12B |
| Hims & Hers Health | 2.58B |
| Lantheus Holdings | 1.56B |
| Indivior Pharmaceuticals | 1.33B |
| Prestige Consumer Healthcare | 1.10B |
| BioCryst Pharmaceuticals | 940.61M |
| Kiniksa Pharmaceuticals International, | 840.85M |
| Supernus Pharmaceuticals | 830.44M |
AMLX News
- 11 days ago - 20 stocks likely to lose money even if the bull market continues - Market Watch
- 12 days ago - Amylyx price target raised to $57 from $55 at Guggenheim - TheFly
- 19 days ago - Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock - Business Wire
- 20 days ago - Amylyx price target raised to $42 from $30 at Mizuho - TheFly
- 20 days ago - Amylyx price target raised to $55 from $40 at Guggenheim - TheFly
- 20 days ago - Amylyx price target raised to $52 from $28 at Baird - TheFly
- 20 days ago - Amylyx price target raised to $39 from $30 at BofA - TheFly
- 20 days ago - Amylyx announces $350M common stock offering - TheFly